Analysis of the Societal Benefits Derived from Reducing Pharmaceutical Prices based on System Dynamics

Authors

  • Yuzhu Zhang
  • Yunxia Cheng
  • Yiting Guo
  • Rong Hu
  • Qiang He

DOI:

https://doi.org/10.62051/z7gx6c77

Keywords:

Pharmaceutical Price; Social Benefits; System Dynamics.

Abstract

The steep prices of pharmaceuticals have long been a significant concern in the healthcare domain, directly impacting patients' financial burdens, government healthcare expenditures, and the operational dynamics of the pharmaceutical market. This study aims to analyze the societal ramifications of lowering drug prices through the lens of system dynamics methodology. Employing a system dynamics model, this study evaluates the effects of drug price adjustments on patients, governments, and the broader society, while also investigating the outcomes across various policy and market scenarios. Findings indicate that reducing drug prices within a certain range can alleviate patients' financial burdens, enhance the accessibility and equity of healthcare services, and decrease government healthcare expenditures, thereby bolstering healthcare coverage. Additionally, the decline in drug prices contributes to narrowing the wealth gap and fostering social equity and stability. The outcomes of this study offer valuable insights for government policy-making and market management in the pharmaceutical sector, facilitating the advancement of a robust pharmaceutical market and societal progress.

Downloads

Download data is not yet available.

References

GOLDMAN D P, JOYCE G F, ESCARCE J J, et al. Pharmacy Benefits and the Use of Drugs by the Chronically Ill[J/OL]. JAMA, 2004, 291(19): 2344-2350. DOI:10.1001/jama.291.19.2344.

LAKDAWALLA D, SOOD N. The Welfare Effects of Public Drug Insurance: w13501[R/OL]. Cambridge, MA: National Bureau of Economic Research, 2007: w13501[2024-05-16]. http://www.nber.org/papers/w13501.pdf. DOI:10.3386/w13501.

ZHOU Z, SU Y, CAMPBELL B, et al. The Financial Impact of the ‘Zero-Markup Policy for Essential Drugs’ on Patients in County Hospitals in Western Rural China[J/OL]. PLOS ONE, 2015, 10(3): e0121630. DOI: 10.1371/ journal. pone.0121630.

KARNON J, EDNEY L, SORICH M. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme[J/OL]. Australian Health Review: A Publication of the Australian Hospital Association, 2017, 41(1): 1-6. DOI:10.1071/AH15122.

KAZI D S, BELLOWS B K, BARON S J, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy[J/OL]. Circulation, 2020, 141(15): 1214-1224. DOI:10.1161/CIRCULATIONAHA.119.045093.

DISTEFANO M J, KANG S Y, YEHIA F, et al. Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs[J/OL]. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 2021, 24(3): 397-403. DOI: 10.1016/j.jval.2020.10.021.

EGILMAN A C, KESSELHEIM A S, AVORN J, et al. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis[J/OL]. JAMA dermatology, 2024, 160(4): 409-416. DOI:10.1001/jamadermatol.2023.6236.

BALIJEPALLI C, GULLAPALLI L, JOSHY J, et al. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health[J/OL]. Journal of Comparative Effectiveness Research, 2024, 13(5): e230178. DOI: 10. 57264/cer-2023-0178.

Tao Qunshan. Analysis of Factors Influencing the Demand for Primary Healthcare Services among Grassroots Masses under the Background of Hierarchical Diagnosis and Treatment: A Study Based on the Grossman Health Demand Model [J/OL]. Journal of Qingdao University of Science and Technology (Social Sciences Edition), 2021, 37(2): 53-59. DOI: 10.16800/j.cnki.jqustss.2021.02.009.

Zhang Huiying, Li Ying, Shui Mei, et al. Exploration of Quality Cost Management of Medical Services under the "Internet + Healthcare" Service Model [J]. Business Observer, 2024, 10(3): 109-112+116.

WYMAN O. 3 Ways Medicare Drug Price Negotiations Will Impact Pharma[EB/OL]. https://www. oliverwyman. com/our-expertise/perspectives/health/2022/aug/3-ways-medicare-drug-price-negotiations-will-impact-pharma. html.

A Strategy for Value-Based Drug Pricing Under the Inflation Reduction Act[EB/OL]//USC Schaeffer. (2023-05-04). https://healthpolicy.usc.edu/article/a-strategy-for-value-based-drug-pricing-under-the-inflation-reduction-act/.

SCHERER F m. The Link Between Gross Profitability and Pharmaceutical R&D Spending[J/OL]. Health Affairs, 2001, 20(5): 216-220. DOI:10.1377/hlthaff.20.5.216.

Downloads

Published

05-06-2024

How to Cite

Zhang, Y., Cheng, Y., Guo, Y., Hu, R., & He, Q. (2024). Analysis of the Societal Benefits Derived from Reducing Pharmaceutical Prices based on System Dynamics. Transactions on Economics, Business and Management Research, 7, 85-92. https://doi.org/10.62051/z7gx6c77